Efficacy and Safety of Relacorilant in Individuals With Adrenal Hypercortisolism: Results From the Phase 3 GRACE and GRADIENT Studies

Badiu et al. • 2025 • ENDO 2025

Read more

Effects of Relacorilant on Pituitary Tumor Volume in Patients With Cushing Disease: Results From the Phase 3 GRACE Study

Dobri et al. • 2025 • International Pituitary Congress

Read more

Treatment of Hypercortisolism in People with Difficult-to-Control Type 2 Diabetes—Final Results of the CATALYST Trial

Pratley, DeFronzo, Aroda, Fonseca, Buse  • 2025 • ADA

Read more

Impact of Relacorilant on Blood Pressure and Antihypertensive Medication Burden in Patients With Hypercortisolism and Hypertension: Results From the GRACE Study

Moraitis et al. • 2025 • Heart in Diabetes 2025

Read more

The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

Plutzky et al. • 2025 • Heart in Diabetes 2025

Read more

High Medication and Cardiovascular Disease Burden in Individuals With Difficult-to-Control Type 2 Diabetes: Clinical Characteristics From the CATALYST Study

DeFronzo et al. • 2025 • Heart in Diabetes 2025

Read more

Characterization of Patients With Difficult-to-Control Type 2 Diabetes and a Post–Dexamethasone Suppression Test Cortisol of 1.2–1.8 μg/dL: Findings From a Large Prospective Study

Busch et al. • 2025 • AACE 2025 Congress

Read more

A Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism

Hannoush et al. • 2025 • AACE 2025 Congress

Read more

Clinical Learnings Based on a Case Series: Considerations for Identifying and Treating Hypercortisolism in Patients with Diabetes

Lucci et al. • 2025 • AACE

Read more

© 2026 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube